New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal ...

Shield is the first FDA-approved blood test for primary colorectal ... that would use blood samples to detect colorectal cancers. The device detects a colon cancer secreted protein known as ...

Mainz Biomed has started the feasibility phase of the PancAlert project to develop a pancreatic cancer screening test.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.

Colorectal cancer screening programs are currently underutilized in Germany. This also applies to testing for blood in the ...

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

Guardant Health's Shield multi-cancer detection (MCD) test has secured the US Food and Drug Administration’s (FDA) ...

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.